糖尿病新世界
糖尿病新世界
당뇨병신세계
Diabetes New World
2015年
20期
40-42
,共3页
糖尿病%重症肺炎%氨溴索
糖尿病%重癥肺炎%氨溴索
당뇨병%중증폐염%안추색
Diabetes%Severe pneumonia%Ambroxol
目的:探讨氨溴索辅助治疗重症肺炎合并糖尿病的临床疗效。方法使用随机数字表法将2014年6月—2015年6月收治的120例重症肺炎合并糖尿病患者分为研究组和对照组(各60例),对照组患者常规应用抗生素、胰岛素进行治疗,研究组在常规治疗基础上加用氨溴索,观察两组患者的临床疗效。结果研究组患者的肺部炎症控制时间、住院时间均显著短于对照组(P<0.05);研究组的治愈率为36.67%,显著高于对照组的21.67%(P<0.05);研究组的总有效率为91.67%,显著高于对照组的66.67%(P<0.05);研究组的病死率显著低于对照组,病灶吸收率显著高于对照组(P<0.05);两组的不良反应发生率比较无明显差异(P>0.05)。结论临床应用氨溴索辅助治疗重症肺炎合并糖尿病,能有效缓解临床症状,加快病灶吸收,提高临床疗效,临床应用优势显著,值得推广。
目的:探討氨溴索輔助治療重癥肺炎閤併糖尿病的臨床療效。方法使用隨機數字錶法將2014年6月—2015年6月收治的120例重癥肺炎閤併糖尿病患者分為研究組和對照組(各60例),對照組患者常規應用抗生素、胰島素進行治療,研究組在常規治療基礎上加用氨溴索,觀察兩組患者的臨床療效。結果研究組患者的肺部炎癥控製時間、住院時間均顯著短于對照組(P<0.05);研究組的治愈率為36.67%,顯著高于對照組的21.67%(P<0.05);研究組的總有效率為91.67%,顯著高于對照組的66.67%(P<0.05);研究組的病死率顯著低于對照組,病竈吸收率顯著高于對照組(P<0.05);兩組的不良反應髮生率比較無明顯差異(P>0.05)。結論臨床應用氨溴索輔助治療重癥肺炎閤併糖尿病,能有效緩解臨床癥狀,加快病竈吸收,提高臨床療效,臨床應用優勢顯著,值得推廣。
목적:탐토안추색보조치료중증폐염합병당뇨병적림상료효。방법사용수궤수자표법장2014년6월—2015년6월수치적120례중증폐염합병당뇨병환자분위연구조화대조조(각60례),대조조환자상규응용항생소、이도소진행치료,연구조재상규치료기출상가용안추색,관찰량조환자적림상료효。결과연구조환자적폐부염증공제시간、주원시간균현저단우대조조(P<0.05);연구조적치유솔위36.67%,현저고우대조조적21.67%(P<0.05);연구조적총유효솔위91.67%,현저고우대조조적66.67%(P<0.05);연구조적병사솔현저저우대조조,병조흡수솔현저고우대조조(P<0.05);량조적불량반응발생솔비교무명현차이(P>0.05)。결론림상응용안추색보조치료중증폐염합병당뇨병,능유효완해림상증상,가쾌병조흡수,제고림상료효,림상응용우세현저,치득추엄。
Objective To evaluate the clinical efficacy of severe pneumonia and diabetes with ambroxol adjuvant treatmen. Methods 120 patients of severe pneumonia and diabetes were divided into study group and the control group (60 cases) by a random number table, The control group used of antibiotics and insulin routine treatment, study group with ambroxol on conventional treatment, observed the clinical efficacy of the two groups of patients. Results Lung inflammation control time and hospitalization time of study group were significantly shorter than the control group(P<0.05); the cure rate of the study group was 36.67%, significantly higher than the 21.67% of control group(P<0.05); the total effective of study group was 91.67%, significantly higher than the 66.67%of control group(P<0.05);mortality rate of study group was significantly lower than the control group, focus absorption rate was significantly higher (P<0.05); there was no significant difference (P>0.05) incidence of adverse reactions between the two groups. Conclusion Use ambroxol adjuvant treatment of severe pneumonia and diabetes, can effectively relieve symptoms, lesions accelerate absorption and improve clinical efficacy. It has significant clinical advantages, should be promoted.